Semaglutide Weight Management and Cardiovascular Risk Reduction
Once-weekly insulin icodec showed HbA1c reduction of -1.55%
after 78 weeks of treatment in phase 3 trial ONWARDS 1
Greater reduction in HbA1c after 78 weeks with insulin icodec
Overall hypoglycaemia in the trial
Change in HbA1c (%-points)
0.0
-0.4
-0.8
-1.2
-1.6
Mean baseline HbA1c: 8.5%
On treatment
N
Once-weekly insulin
icodec
Once-daily insulin
glargine U100
(%) E R N (%) E R
Level 2: Clinically
significant hypo
61
(12.4) 226 0.30
66
(13.4) 114
0.15
Level 3:
1
0.2
1
0.001
6 (1.2) 7
0.009
Severe hypo
-1.44%
-1.55%
Level 3 or 2:
Severe or
61
(12.4)
227
0.30
70
clinically
0
(14.2) 121
0.16
significant hypo
-2.0
0 10 18 26
36 44
52 62 70
78 78*
Once-weekly insulin Icodec
Once-daily insulin glargine U100
Note: Observed data are in-trial. Week 78* is estimated mean change in HbA1c based on ANCOVA with missing data derived
from multiple imputation
Note: Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by blood
glycose meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external
assistance for recovery. Data is on-treatment.
N: Number of patients with one or more events; %: Percentage of patients with one or more events; E: Number of events;
R: Rate (number of events per patient year of exposure; Hypo: HypoglycaemiaView entire presentation